These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2010626)

  • 1. Anti-HIV activity of CD4-Pseudomonas exotoxin on infected primary human lymphocytes and monocyte/macrophages.
    Ashorn P; Englund G; Martin MA; Moss B; Berger EA
    J Infect Dis; 1991 Apr; 163(4):703-9. PubMed ID: 2010626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-HIV effects of CD4-Pseudomonas exotoxin on human lymphocyte and monocyte/macrophage cell lines.
    Ashorn P; Moss B; Berger EA
    Ann N Y Acad Sci; 1990; 616():149-54. PubMed ID: 2078015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD4-Pseudomonas exotoxin hybrid protein blocks the spread of human immunodeficiency virus infection in vitro and is active against cells expressing the envelope glycoproteins from diverse primate immunodeficiency retroviruses.
    Berger EA; Clouse KA; Chaudhary VK; Chakrabarti S; FitzGerald DJ; Pastan I; Moss B
    Proc Natl Acad Sci U S A; 1989 Dec; 86(23):9539-43. PubMed ID: 2480605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous presence of CD4-PE40 is required for antiviral activity against single-passage HIV isolates and infected peripheral blood mononuclear cells.
    Winters MA; Merigan TC
    AIDS Res Hum Retroviruses; 1993 Nov; 9(11):1091-6. PubMed ID: 8312052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-HIV-1 immunotoxin 3B3(Fv)-PE38: enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques.
    Kennedy PE; Bera TK; Wang QC; Gallo M; Wagner W; Lewis MG; Berger EA; Pastan I
    J Leukoc Biol; 2006 Nov; 80(5):1175-82. PubMed ID: 16923920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors.
    Ashorn P; Moss B; Weinstein JN; Chaudhary VK; FitzGerald DJ; Pastan I; Berger EA
    Proc Natl Acad Sci U S A; 1990 Nov; 87(22):8889-93. PubMed ID: 1701055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of CD4-Pseudomonas exotoxin against cells expressing diverse forms of the HIV and SIV envelope glycoproteins.
    Ashorn P; Moss B; Berger EA
    J Acquir Immune Defic Syndr (1988); 1992; 5(1):70-7. PubMed ID: 1738090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unique insertion sequence and pattern of CD4 expression in variants selected with immunotoxins from human immunodeficiency virus type 1-infected T cells.
    Fang H; Pincus SH
    J Virol; 1995 Jan; 69(1):75-81. PubMed ID: 7983770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative assay for testing susceptibility of HIV isolates to zidovudine and sCD4 (178)-PE40.
    Verhoef J; Gekker G; Erice A; Peterson PK; Balfour HH
    Eur J Clin Microbiol Infect Dis; 1992 Aug; 11(8):715-21. PubMed ID: 1425730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD4-Pseudomonas exotoxin conjugates delay but do not fully inhibit human immunodeficiency virus replication in lymphocytes in vitro.
    Tsubota H; Winkler G; Meade HM; Jakubowski A; Thomas DW; Letvin NL
    J Clin Invest; 1990 Nov; 86(5):1684-9. PubMed ID: 2243139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant CD4-Pseudomonas exotoxin hybrid protein displays HIV-specific cytotoxicity without affecting MHC class II-dependent functions.
    Berger EA; Chaudhary VK; Clouse KA; Jaraquemada D; Nicholas JA; Rubino KL; Fitzgerald DJ; Pastan I; Moss B
    AIDS Res Hum Retroviruses; 1990 Jun; 6(6):795-804. PubMed ID: 2114147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein.
    Chaudhary VK; Mizukami T; Fuerst TR; FitzGerald DJ; Moss B; Pastan I; Berger EA
    Nature; 1988 Sep; 335(6188):369-72. PubMed ID: 2843774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of recombinant soluble CD4 (rCD4) on HIV-1 infection of monocyte/macrophages.
    Harbison MA; Gillis JM; Pinkston P; Byrn RA; Rose RM; Hammer SM
    J Infect Dis; 1990 Jan; 161(1):1-6. PubMed ID: 2295841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Failure of short-term CD4-PE40 infusions to reduce virus load in human immunodeficiency virus-infected persons.
    Ramachandran RV; Katzenstein DA; Wood R; Batts DH; Merigan TC
    J Infect Dis; 1994 Oct; 170(4):1009-13. PubMed ID: 7930696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific killing of HIV-infected lymphocytes by a recombinant immunotoxin directed against the HIV-1 envelope glycoprotein.
    Bera TK; Kennedy PE; Berger EA; Barbas CF; Pastan I
    Mol Med; 1998 Jun; 4(6):384-91. PubMed ID: 10780881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of dichotomous action of IL-2-Pseudomonas exotoxin 40 (IL-2-PE40) on cell-mediated and humoral immune response.
    Volk HD; Müller S; Yarkoni S; Diamantstein T; Lorberboum-Galski H
    J Immunol; 1994 Sep; 153(6):2497-505. PubMed ID: 8077661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary HIV-1 isolates refractory to neutralization by soluble CD4 are potently inhibited by CD4-Pseudomonas exotoxin.
    Kennedy PE; Moss B; Berger EA
    Virology; 1993 Jan; 192(1):375-9. PubMed ID: 8517027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale for the use of immunotoxins in the treatment of HIV-infected humans.
    Van Oijen MG; Preijers FW
    J Drug Target; 1998; 5(2):75-91. PubMed ID: 9588864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4-Pseudomonas exotoxin hybrid proteins: modulation of potency and therapeutic window through structural design and characterization of cell internalization.
    Winkler G; Jakubowski A; Turner S; Liu T; Burrus B; McGray P; Heanue T; Rosa M; Griffiths BA; Wali A
    AIDS Res Hum Retroviruses; 1991 Apr; 7(4):393-401. PubMed ID: 2069820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different pattern of activity of inhibitors of the human immunodeficiency virus in lymphocytes and monocyte/macrophages.
    Perno CF; Yarchoan R; Balzarini J; Bergamini A; Milanese G; Pauwels R; De Clercq E; Rocchi G; Calio R
    Antiviral Res; 1992 Apr; 17(4):289-304. PubMed ID: 1322645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.